EpiStem is a biotechnology company commercialising adult stem cells in the areas of oncology and gastrointestinal diseases as well as cosmeceutical applications. the Company originally formed part of the Paterson Institute for Cancer Research, UK. The founders and management are international experts in epithelial tissue, tumours and stem cell control and lead a team of experienced scientific staff, with specialist skills in the field. EpiStem develops innovative therapeutics and diagnostic biomarkers and provides contract research services to drug development companies. The Group’s expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. EpiStem does not conduct research in the areas of embryonic stem cells or stem cell transplantation. EpiStem operates two distinct business divisions, Contract Research Services and Novel Therapies. Contract Research Services provides specialised preclinical efficacy testing primarily for drug development companies on a fee for service basis and provides specialised preclinical assays for drug development in the areas of oncology supportive care, oncology, inflammatory bowel disease (IBD), and new emerging applications. Novel Therapies is focused on developing its own innovative therapeutics and diagnostic biomarkers.